Goodrx 2025 Q2 Earnings Net Income Surges 91.9%

Goodrx (GDRX) reported its fiscal 2025 Q2 earnings on August 7, 2025, meeting expectations with a 1% revenue increase and a notable 91.9% rise in net income. The company adjusted its guidance downward for revenue due to external factors like the Rite Aid bankruptcy and a PBM volume reduction, but it maintained its Adjusted EBITDA outlook between $265 million and $275 million for 2025, reflecting 2% to 6% growth.

Revenue
Goodrx reported total revenue of $203.07 million for 2025 Q2, a 1.2% increase compared to $200.61 million in 2024 Q2. Prescription transactions accounted for the largest share at $143.06 million, followed by pharma manufacturer solutions revenue at $34.98 million. Subscription revenue totaled $20.46 million, and other revenue added $4.56 million to the revenue mix.

Earnings/Net Income
Earnings surged for Goodrx in 2025 Q2, with EPS more than doubling to $0.04 from $0.02 in the same period last year. The company's net income also saw strong growth, increasing to $12.84 million in 2025 Q2, up from $6.69 million in 2024 Q2, marking a 91.9% growth year-over-year. These results indicate a strong earnings performance driven by operational efficiencies and cost management.

Price Action
The stock price of Goodrx experienced significant volatility in the aftermath of the earnings report. On the latest trading day, the stock dropped 13.25%, and over the full trading week, it declined by 27.56%. Month-to-date, GDRX fell 28.31%, showing a sharp divergence from typical post-earnings performance for companies with similar results.

Post Earnings Price Action Review
The stock of Goodrx performed poorly in the 30 days following the earnings report. A strategy of buying on the earnings beat and holding for 30 days resulted in a loss of -91.06%, significantly underperforming the benchmark by 131.74%. This performance highlights the market's negative sentiment toward the company despite its strong earnings, with the Sharpe ratio of -0.64 and maximum drawdown of 0% indicating high risk and minimal returns for investors.

CEO Commentary
Wendy Barnes, Chief Executive Officer and President of GoodRx, emphasized the company's progress in executing key initiatives aimed at sustainable long-term growth. She highlighted successful expansions in integrated access and affordability solutions with pharma partners, the completion of new pharmacy counter and e-commerce deals, and the launch of a condition subscription product for erectile dysfunction. Barnes expressed confidence in the company's momentum and its ability to reduce friction in the healthcare system.

Guidance
For the full year 2025, Goodrx expects revenue to increase from 2024 levels. The company anticipates Adjusted EBITDA to range between $265 million and $275 million, reflecting a year-over-year growth of 2% to 6% compared to 2024's Adjusted EBITDA of $260.2 million. This guidance reflects the company's strategic focus on profitability and operational efficiency, despite the anticipated headwinds from external factors.

Additional News
Goodrx repurchased 10.2 million shares of Class A common stock in the second quarter of 2025 for $46.4 million, with $143 million of unused share repurchase capacity remaining under its $450 million repurchase program. The company is also expanding its integrated access and affordability solutions with pharma, including new deals for pharmacy counter and e-commerce. Additionally, the launch of a condition-specific subscription product for erectile dysfunction marks a strategic move into new markets. These initiatives highlight Goodrx's commitment to innovation and long-term growth in the healthcare savings sector.